B-cell Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for B-cell Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-10EMA Authorised: Venclyxto (venetoclax) — AbbVie Deutschland GmbH & Co. KG
EMA confirms authorisation of Venclyxto (venetoclax) for chronic lymphocytic leukemia and related B-cell leukemias; product is authorised fo…
-
EMA approval · 2026-07-08EMA Authorised: Venclyxto (venetoclax) — AbbVie Deutschland GmbH & Co. KG
EMA authorises Venclyxto (venetoclax) for chronic lymphocytic leukemia and related B-cell leukemias, broadening its approved therapeutic use…
-
EMA withdrawal · 2019-05-10EMA Withdrawn: Arzerra (ofatumumab) — Novartis Europharm Ltd
EMA has withdrawn Arzerra (ofatumumab) from the market in Europe.